Highlights Prescient Therapeutics Limited

Equities

PTX

AU000000PTX3

Market Closed - Australian S.E. Other stock markets 01:57:18 2024-06-21 EDT			5-day change	1st Jan Change
0.0405 ^AUD	+1.25%		-5.81%	-34.68%

03-25	Transcript : Prescient Therapeutics Limited - Special Call
02-23	Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-22	CI
Prescient Therapeutics Receives AU$2.4 Million R&D Tax Rebate; Shares Down 4%	11-27	MT
Prescient Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-24	CI
Prescient Therapeutics Limited Provides an Update on the PTX-100 Phase 1b Expansion Cohort in Relapsed and Refractory T Cell Lymphomas	23-03-15	CI
Prescient Therapeutics Announces FDA Grants Broader Orphan Drug Status to PTX-100 for TCL Indications	23-03-08	CI
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Prescient Therapeutics Limited Announces PTX-100 Trial Update	22-10-24	CI
Prescient Therapeutics Unveils CellPryme-A to Boost Car-T Performance	22-09-22	CI
Prescient Therapeutics, MD Anderson Cancer Center to Develop Blood Cancer Binder for OmniCAR; Shares Rise 3%	22-09-06	MT
Prescient Therapeutics Announces a Strategic Collaboration with the Larger Cancer Centre in the US1, the University of Texas MD Anderson Cancer Center	22-09-06	CI
Prescient Therapeutics Limited Signs Agreement with Thermo Fisher Scientific to Accelerate OmniCAR Platform Development	22-08-17	CI
Prescient Therapeutics Secures Orphan Drug Designation in US for Lymphoma Drug; Shares Rally 19%	22-07-14	MT
Prescient Therapeutics Secures US Patent for OmniCAR Platform; Shares Rise 6%	22-07-04	MT
Prescient Therapeutics Limited Unveils New Clinic-Ready CAR-T Enhancement Platform	22-06-07	CI
Prescient Therapeutics Limited Expands PTX-200 AML Cohort Following Additional Complete Remission	22-05-08	CI
Prescient Therapeutics Limited Announces Opening of Enrolment in the Expansion Cohort of the Phase 1b Trial of PTX-100 to Treat T-Cell Lymphomas	22-04-04	CI
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2021	22-02-24	CI
Prescient Therapeutics Limited Data Demonstrates Key OmniCAR Features in Next Gen Car-T	21-10-12	CI
Prescient Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2021	21-08-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Prescient Therapeutics Limited

Equities

PTX

AU000000PTX3

Highlights

Filters